Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jun;79(2):171-91.
doi: 10.1128/MMBR.00051-14.

Lantibiotic resistance

Affiliations
Review

Lantibiotic resistance

Lorraine A Draper et al. Microbiol Mol Biol Rev. 2015 Jun.

Abstract

The dramatic rise in the incidence of antibiotic resistance demands that new therapeutic options will have to be developed. One potentially interesting class of antimicrobials are the modified bacteriocins termed lantibiotics, which are bacterially produced, posttranslationally modified, lanthionine/methyllanthionine-containing peptides. It is interesting that low levels of resistance have been reported for lantibiotics compared with commercial antibiotics. Given that there are very few examples of naturally occurring lantibiotic resistance, attempts have been made to deliberately induce resistance phenotypes in order to investigate this phenomenon. Mechanisms that hinder the action of lantibiotics are often innate systems that react to the presence of any cationic peptides/proteins or ones which result from cell well damage, rather than being lantibiotic specific. Such resistance mechanisms often arise due to altered gene regulation following detection of antimicrobials/cell wall damage by sensory proteins at the membrane. This facilitates alterations to the cell wall or changes in the composition of the membrane. Other general forms of resistance include the formation of spores or biofilms, which are a common mechanistic response to many classes of antimicrobials. In rare cases, bacteria have been shown to possess specific antilantibiotic mechanisms. These are often species specific and include the nisin lytic protein nisinase and the phenomenon of immune mimicry.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Mechanisms of lantibiotic resistance which relate to the cell wall and membrane. (A) d-Alanylation of lipoteichoic acids (LTA) and wall teichoic acids (WTA) by the dltABCD operon, which confers a positive charge. (B) Changes in phospholipid composition. (C) Changes in membrane fatty acid composition. (D) Cell wall thickening. (E) Lysine esterification of one of the two hydroxyl groups of phosphatidylglycerol (PG) by Mprf. (F) Gram-negative outer cell membrane containing lipopolysaccharide (LPS).
FIG 2
FIG 2
Two main types of two-component systems (TCSs) are responsible for lantibiotic resistance: the Bce-like TCSs (A) and the Lia-like TCSs (B). The presence of antimicrobials, such as lantibiotics, or the cell damage incurred as a result of their presence causes these TCSs to mediate the transcription of genes whose products confer a resistance phenotype.
FIG 3
FIG 3
In S. aureus, three main TCSs are responsible for lantibiotic/antimicrobial resistance. These include two Bce-like TCSs, BraRS and GraRS, and an Lia-like TCS, VraSR. A coordinated resistance effort results from the actions of these TCSs, causing upregulation of genes whose products alter the composition of the cell wall and membrane and also of genes encoding ABC transporters which expel antimicrobials from the cell.
None
None
None
None

References

    1. Rea MC, Ross RP, Cotter PD, Hill C. 2011. Classification of bacteriocins from Gram-positive bacteria, p 29–53. In Drider D, Rebuffat S (ed), Prokaryotic antimicrobial peptides. Springer, New York, NY.
    1. Wiedemann I, Breukink E, van Kraaij C, Kuipers OP, Bierbaum G, de Kruijff B, Sahl HG. 2001. Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J Biol Chem 276:1772–1779. doi: 10.1074/jbc.M006770200. - DOI - PubMed
    1. Cotter PD, Hill C, Ross RP. 2005. Bacterial lantibiotics: strategies to improve therapeutic potential. Curr Protein Pept Sci 6:61–75. doi: 10.2174/1389203053027584. - DOI - PubMed
    1. Piper C, Cotter PD, Ross RP, Hill C. 2009. Discovery of medically significant lantibiotics. Curr Drug Discov Technol 6:1–18. doi: 10.2174/157016309787581075. - DOI - PubMed
    1. Cotter PD, Ross RP, Hill C. 2013. Bacteriocins—a viable alternative to antibiotics? Nat Rev Microbiol 11:95–105. doi: 10.1038/nrmicro2937. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources